Kura Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kura Oncology, Inc. on June 27, 2019, regarding events occurring on June 25, 2019. The filing details the results of the Company's Annual Meeting of Stockholders. As of the record date of April 26, 2019, there were 38,184,547 shares of common stock outstanding.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
At the Annual Meeting, 29,155,724 shares were present in person or by proxy. The following matters were submitted to a vote:
- Election of Directors: Stockholders elected Robert E. Hoffman and Thomas Malley as Class II directors for three-year terms.
- Ratification of Auditors: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Key Voting Data
| Proposal | For | Against/Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Robert E. Hoffman | 18,970,622 | 7,510,975 (Withheld) | N/A | 2,674,127 |
| Election of Thomas Malley | 20,760,577 | 5,721,020 (Withheld) | N/A | 2,674,127 |
| Ratify Ernst & Young LLP | 26,630,742 | 75,309 | 2,449,673 | 0 |
Outlook and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected Class II directors (Robert E. Hoffman and Thomas Malley) through the 2022 Annual Meeting.
- Confirm the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2019.
- Note the significant number of broker non-votes (2,674,127) regarding the director elections, indicating shares held by brokers that could not be voted without specific instructions.